436 Studies Now Enrolling
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimers Disease (MissionAD1)
MissionAD1: A 24-month Efficacy and Safety Study in Subjects with Early Alzheimer's Disease
| Sponsor: | EISAI |
| Enrolling: | Male and Female Patients |
| Study Length: | 24 Months |
| IRB Number: | AAAR2556 |
| U.S. Govt. ID: | NCT02956486 |
| Contact: | Evelyn D. Dominguez: 212-305-2371 / edd5@cumc.columbia.edu |
Additional Study Information:
The name of this trial is MissionAD. This is a 24-month treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 3 study in participants with Early Alzheimer's Disease (AD), includingmild cognitive impairment (MCI) due to AD, known as Prodromal AD, and the early stages of mild AD.The study will be conducted to evaluate the efficacy and safety of E2609, whose proposed international nonproprietary name is elenbecestat.
This study is closed
Do You Qualify?
| Do you have mild cognitive impairment due to Alzheimer's disease or mild AD dementia? | Yes | No |
| Do you have a study partner able to support your partiipation for the duration of the study? | Yes | No |
| Have you had a stroke or mini stroke in the past 12 months? | Yes | No |
| Do you have a history of seizures within the past 5 years? | Yes | No |